COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,699 Articles (22,913 medRxiv, 8,786 bioRxiv)

Most recent first Previous |  Page 1786: Articles 17851-17860  | Next

Predictive Capacity of COVID-19 Test Positivity Rate
Fenga, L., Gaspari, M.
10.1101/2021.03.04.21252897 — Posted: 2021-03-08
Development and Implementation of a scalable and versatile test for COVID-19 diagnostics in rural communities
Ceci, A., Munoz-Ballester, C., Tegge, A., Brown, K. L., Umans, R. A., Michel, F. M., Patel, D., Tewari, B., Martin, J., Alcoreza, O., Maynard, T., Martinez-Martinez, D., Bordwine, P., Bisell, N., Friedlander, M., Sontheimer, H., Finkielstein, C. V.
10.1101/2021.03.01.21252679 — Posted: 2021-03-08
Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study
Mikhaylov, E. N., Lyubimtseva, T. A., Vakhrushev, A. D., Stepanov, D., Lebedev, D. S., Vasilieva, E. Y., Konradi, A. O., Shlyakhto, E. V.
10.1101/2021.03.03.21252855 — Posted: 2021-03-08 Discussion: Onsite
Estimation and optimal control of the multi-scale dynamics of the Covid-19
FOTSA MBOGNE, D. J., TCHOUMI, S. Y., Kouakep Tchaptchie, Y., KAMLA, V. C., KAMGANG, J. C., HOUPA DANGA, D. E., BOWONG TSAKOU, S., BEKOLLE, D.
10.1101/2021.03.04.21252880 — Posted: 2021-03-08
Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected persons
Demonbreun, A. R., Sancilio, A., Velez, M. E., Ryan, D. T., Saber, R., Vaught, L. A., Reiser, N. L., D'Aquila, R. T., Mustanski, B., McNally, E. M., McDade, T. W.
10.1101/2021.03.04.21252913 — Posted: 2021-03-08
Estimating the super-spreading rate at workplaces using bluetooth technology
Vazquez, A., Staebler, M., Khanin, A., Lichte, D., Brucherseifer, E.
10.1101/2021.03.04.21252550 — Posted: 2021-03-08
Measuring the exposure of Black, Asian and other ethnic groups to Covid-infected neighbourhoods in English towns and cities
Harris, R., Brunsdon, C.
10.1101/2021.03.04.21252893 — Posted: 2021-03-08
Recommendations for COVID-19 Vaccination in People with Rheumatic Disease: Developed by the Singapore Chapter of Rheumatologists
Santosa, A., Xu, C., Arkachaisri, T., Kong, K. O., Lateef, A., Lee, T. H., Leong, K. H., Low, A. H., Sriranganathan, M. K., Tan, T. C., Teng, G. G., Thong, B. Y., Fong, W., Lahiri, M.
10.1101/2021.03.01.21252653 — Posted: 2021-03-08
Self-reported real-world safety and reactogenicity of COVID-19 vaccines: An international vaccine-recipient survey.
Mathioudakis, A. G., Ghrew, M., Ustianowski, A., Ahmad, S., Borrow, R., Papavasileiou, L. P., Petrakis, D., Bakerly, N. D.
10.1101/2021.02.26.21252096 — Posted: 2021-03-08 Discussion: Onsite
We also deserve help during the pandemic: The effect of the COVID-19 pandemic on foreign domestic workers in Hong Kong
Lui, I. D., Vandan, N., Davies, S. E., Harman, S., Morgan, R., Smith, J., Wenham, C., Grepin, K. A.
10.1101/2021.03.04.21252889 — Posted: 2021-03-08

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).